Lam J, et al. – In this study, researchers adopted a Markov model to examine the comparative cost-effectiveness of add-on reslizumab with the standard-of-care (SOC) from the US societal perspective over a 5-year time span. Authors calculated the mortality rates, costs, and utility from literature, the CDC, the US Department of Veterans Affairs, and the Centers for Medicare and Medicaid Services (CMS). They noted that response and adherence models had lower ICERs vs base model but still above $500,000. They concluded that reslizumab is unlikely cost-effective as improvement in quality of life and exacerbation rates were associated with high costs.